<DOC>
	<DOCNO>NCT02108639</DOCNO>
	<brief_summary>Assess effect renal function blood level DCV , ASV , BMS-791325 .</brief_summary>
	<brief_title>To Assess Effect Renal Impairment Blood Levels Daclatasvir ( DCV ) , Asunaprevir ( ASV ) BMS-791325 After Multiple Doses Fixed Dose Combination Tablet</brief_title>
	<detailed_description>IND Number : 79,599/101,943 Primary Purpose : Other - Phase 1 Clinical Pharmacology study determine effect renal impairment exposure DCV , ASV , BMS-791325 ( fix dose combination ) BMS-791325 give multiple dos Fixed dose combination ( FDC ) Fixed Dose Combination Daclatasvir , Asunaprevir BMS-791325 ( DCV 3DAA FDC )</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Subjects Group A must good health normal renal function Subjects Groups BE may clinical , Electrocardiogram ( ECG ) laboratory finding consistent degree renal dysfunction Women childbearing potential ( WOCBP ) male participant must agree follow require contraceptive method Subjects Group A must significant acute chronic illness Subjects Groups BE must uncontrolled unstable cardiovascular , respiratory , hepatic , gastrointestinal , endocrine , hematopoietic , and/or neurological disease within 6 month screen Subjects Groups BE may evidence rapidly deteriorate renal function , define screen creatinine clearance ( CLcr ) decrease previous CLcr 50 % within last 3 month Prior exposure DCV , ASV BMS791325 within 3 month prior study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>